Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
353,70 €
+0,2 €
+0,06%
14:32:26 Uhr
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,93%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-

Roche Holding News

23.05.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Positive recommendation based on phase III INAVO120 data showing Itovebi TM (inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-​free ...
23.05.25 - GlobeNewswire
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology 1 , with an initial focus on critically ill newborns ...
23.05.25 - GlobeNewswire
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with ...
22.05.25 - GlobeNewswire
FDA approves Roche’s Susvimo for diabetic retinopathy
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months Susvimo’s innovative ...
20.05.25 - GlobeNewswire
Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the phase III STARGLO study 1,2 There is an ...
14.05.25 - GlobeNewswire
Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis
The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-​expressed in some patients with non-​squamous non-small cell lung cancer ...
13.05.25 - GlobeNewswire
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and ...
06.05.25 - GlobeNewswire
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 ...
30.04.25 - GlobeNewswire
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
Positive recommendation based on clinical, real-​world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example ...
29.04.25 - GlobeNewswire
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment.  The device ...
25.04.25 - GlobeNewswire
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household ...
24.04.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter
Group sales grew by 6% 1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. Pharmaceuticals Division sales ...
24.04.25 - GlobeNewswire
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachs­tums­kurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort
Konzernverkäufe stiegen um 6% 1 zu konstanten Wechselkursen (CER; 7% in CHF) dank hoher Nachfrage nach innovativen Medikamenten und diagnostischen Lösungen. ...
23.04.25 - GlobeNewswire
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device 1 set to transform cardiac care This ...
22.04.25 - GlobeNewswire
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
USD 50 billion commitment includes new state-​of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, ...

Newssuche

Videos

newspaper
16.04.26 +0,31%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »